Saudi Arabia Biotechnology Market By Product Type (Instruments, Reagents, Software and Services), By Technology (Nanobiotechnology, Tissue Engineering and Regeneration, DNA Sequencing, Cell-Based Assays, Fermentation, PCR Technology, Chromatography, Other), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

Saudi Arabia Biotechnology Market was valued at USD 224.36 Million in 2024 and is expected to reach USD 277.09 Million by 2030 with a CAGR of 3.78% during the forecast period. The biotechnology market in Saudi Arabia is experiencing rapid growth, driven by the country’s strategic initiatives to diversify its economy and strengthen its healthcare infrastructure. As part of the Vision 2030 framework, Saudi Arabia aims to transform into a global leader in innovation and technology, with biotechnology playing a central role in achieving this goal. The market is expanding across various sectors, including pharmaceuticals, agriculture, diagnostics, and biofuels, supported by robust government investment and a growing demand for advanced healthcare solutions.

Saudi Arabia's healthcare sector is undergoing rapid transformation, with biotechnology poised to play a crucial role in advancing medical treatments and diagnostics. The increasing prevalence of chronic diseases, along with the demand for personalized medicine, has created substantial growth opportunities in the biotechnology market, particularly in the fields of genetic research, immunotherapy, and drug development.

Despite the promising outlook, the biotechnology market in Saudi Arabia faces challenges, including the need for skilled talent, access to cutting-edge research facilities, and the potential for intellectual property protection issues. Additionally, building a domestic biotechnology ecosystem that can compete on a global scale will require sustained investment in R&D, collaboration between academia and industry, and a greater focus on long-term sustainability.

Key Market Drivers

Growth in Healthcare Industry

The rapid growth of the healthcare industry in Saudi Arabia is playing a pivotal role in driving the expansion of its biotechnology market. The Ministry of Health (MOH) is a governmental entity within the Saudi Cabinet responsible for formulating and executing health policies, overseeing and regulating the healthcare sector, and safeguarding and promoting public health. Its mission is to support the achievement of the nation's vision for a dynamic, healthy society, which serves as the cornerstone for economic prosperity. With a strong focus on improving healthcare infrastructure, advancing medical research, and enhancing the quality of life for its citizens, Saudi Arabia has become a fertile ground for biotechnology innovation and investment.

The demand for cutting-edge biotechnology solutions, including genetic testing, personalized medicine, and advanced therapeutics, is rising due to the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions in the Saudi population. This, in turn, is spurring investment in biotechnology research and product development, creating new opportunities for both local and international players in the market.

Additionally, the establishment of world-class healthcare facilities, such as hospitals and research centers, alongside the country's push for medical tourism, further strengthens the biotechnology market. The focus on fostering innovation through public-private partnerships, investment in clinical trials, and regulatory reforms designed to support biotechnology development are also contributing factors to the sector's growth.

Surge in Technological Advancements

The surge in technological advancements is a pivotal driver of Saudi Arabia's biotechnology market, fostering significant growth and transformation across the sector. Over the past few years, technological innovations in fields such as gene editing, artificial intelligence (AI), and nanotechnology have accelerated the development of advanced biotechnological solutions, positioning Saudi Arabia as a key player in the global biotech landscape.

In January 2024, Saudi Arabia launched a national biotechnology strategy aimed at establishing the country as a global biotech hub within the next 16 years. This initiative is a key component of Vision 2030, a broader national project that seeks to position Saudi Arabia as a biotech leader in the Middle East and North Africa region by 2030. The National Biotechnology Strategy will enhance the country's capabilities in four key areas: vaccines, biomanufacturing and localization, genomics, and plant optimization.

These advancements have facilitated the rapid development of new drugs, diagnostics, and therapies, addressing both local and global healthcare needs. The country has seen an increasing adoption of cutting-edge technologies in pharmaceutical research and development, healthcare diagnostics, and agricultural biotechnology. With a growing emphasis on personalized medicine and precision healthcare, Saudi Arabia’s biotech industry is leveraging these innovations to enhance treatment efficacy and improve patient outcomes.

As technological advancements continue to reshape the biotech landscape, Saudi Arabia is poised to strengthen its position as a leader in biotechnology innovation, attracting both local and international investments while addressing critical health and environmental challenges. This surge in technological progress promises to drive the country’s biotech market forward, contributing to its economic diversification and growth in line with Vision 2030.

Download Free Sample Report

Key Market Challenges

Limited Infrastructure and Facilities

Biotechnology is a research-intensive industry, and the success of biotech companies relies heavily on access to state-of-the-art laboratories and specialized research facilities. In Saudi Arabia, although some universities and institutions, such as King Abdullah University of Science and Technology (KAUST), have made significant investments in biotech research, there is still a need for more widespread, cutting-edge R&D infrastructure across the country. The lack of an extensive network of high-tech labs, bioreactors, and facilities dedicated to the testing and development of new biotech products limits the ability of local startups and established companies to innovate at the pace required to stay competitive on a global scale.

A significant challenge stemming from limited infrastructure is the scarcity of skilled personnel to operate and manage advanced biotech facilities. The biotechnology sector requires highly specialized talent in areas such as molecular biology, bioinformatics, and biomanufacturing. While Saudi Arabia has made strides in enhancing education and training in the sciences, the country still faces challenges in attracting and retaining top-tier professionals due to the relative underdevelopment of the biotech infrastructure and the limited availability of career opportunities in some specialized fields. This talent gap poses a significant barrier to establishing world-class research facilities and scaling biotech operations effectively.

Key Market Trends

Surge in Agricultural Biotechnology

A significant trend driving the growth of Saudi Arabia's biotechnology market is the surge in agricultural biotechnology. With the country’s challenging arid climate and limited arable land, agricultural innovation has become a critical focus in Saudi Arabia's efforts to ensure food security and sustainable agricultural practices. Agricultural biotechnology, which encompasses the use of genetic engineering, molecular biology, and advanced breeding techniques, plays a crucial role in addressing these challenges.

In November 2024, the Kingdom of Saudi Arabia (KSA) introduced regulations permitting the import of biotech plant products, with a requirement for labeling if they contain more than one percent genetically engineered (GE) plant ingredients. Saudi Arabia is a significant importer of biotech U.S. corn and soybeans. While the import of biotech planting seeds is allowed, there are currently no commercial development activities for GE plants within the country.

Biotechnology-driven advancements are addressing several key issues within the agricultural sector, such as water scarcity, soil degradation, and climate change. By developing drought-resistant crops and enhancing crop resilience, agricultural biotechnology helps Saudi Arabia meet the growing demand for food while managing its limited water resources more efficiently. Furthermore, the incorporation of biotech solutions aids in increasing the nutritional value of crops, which contributes to improved public health outcomes.

In July 2024, BGI Group announced its role as a founding member of the newly established Saudi AgriFood Tech Alliance. This significant event, hosted by the Saudi Ministry of Environment, Water, and Agriculture (MEWA), marks a key milestone in BGI’s dedication to advancing agri-food technology and fostering sustainable agricultural development in Saudi Arabia and the wider Middle East region.

Segmental Insights

Product Type Insights

Based on Product Type, Instruments have emerged as the fastest growing segment in the Saudi Arabia Biotechnology Market in 2024. Saudi Arabia is increasingly investing in improving its healthcare infrastructure, with a particular focus on precision medicine, genomics, and personalized healthcare. This shift has driven the demand for sophisticated diagnostic tools and laboratory instruments that are critical for conducting advanced medical tests, such as genetic sequencing, molecular diagnostics, and biomarker identification.

Instruments like PCR machines, flow cytometers, and DNA sequencers are essential in these areas, leading to significant growth in the demand for high-tech equipment. As the country aims to enhance its diagnostic capabilities and reduce reliance on international healthcare solutions, the market for instruments used in medical diagnostics continues to expand rapidly.

Technology Insights

Based on Technology, Nanobiotechnology have emerged as the fastest growing segment in the Saudi Arabia Biotechnology Market during the forecast period. One of the primary drivers behind the rise of nanobiotechnology is its transformative impact on the healthcare industry. Nanobiotechnology allows for the development of highly targeted drug delivery systems, improved diagnostic tools, and advanced biomaterials.

These innovations have the potential to significantly enhance the effectiveness of medical treatments, offering new solutions for diseases such as cancer, diabetes, and cardiovascular conditions. As healthcare demand increases in Saudi Arabia, especially under the Vision 2030 initiative's goal to modernize and expand healthcare infrastructure, the adoption of nanobiotechnology is accelerating.

Download Free Sample Report

Regional Insights

Based on Region, Northern & Central have emerged as the dominating region in the Saudi Arabia Biotechnology Market in 2024. This is due to a combination of strategic investments, infrastructure development, and proximity to key government initiatives. These regions are at the forefront of the country's biotechnology advancements, driven by several key factors. The Central region, which includes Riyadh, the capital, serves as the hub of Saudi Arabia's political, economic, and scientific activities. The concentration of government agencies, research institutions, and major healthcare organizations in Riyadh has created a favorable environment for biotech innovations and collaborations. The city’s robust infrastructure, skilled workforce, and growing emphasis on research and development (R&D) have positioned it as a magnet for biotech companies and investors.

Recent Development

• In December 2024, Saudi Arabia’s Ministry of Industry and Mineral Resources, in partnership with the Ministries of Investment and Health, signed a memorandum of understanding (MoU) with Vertex Pharmaceuticals to establish gene therapy manufacturing capabilities within the Kingdom. The agreement aims to drive research and development, enhance local biomanufacturing capabilities, and provide training for Saudi talent in biotechnology.
• In January 2025, Lifera hosted global biotech leaders in Riyadh to discuss the future of biotechnology in Saudi Arabia. The landmark event featured a groundbreaking panel discussion titled "Elevating Saudi Biotech to Global Heights," bringing together some of the most influential figures in the biotech industry. This distinguished gathering included individuals who have collectively invested over USD 50 billion in biotech and founded more than 200 companies, many of which are leaders in their respective fields.
• In December 2024, the KAIMRC Medical Biotechnology Park launched a series of Innovation Programs focused on fostering strategic partnerships with government, academic, and industrial organizations both locally and globally. The initiative aims to support Saudi Arabia’s ongoing economic transformation from one reliant on natural resources to one driven by knowledge and innovation, with a particular emphasis on medical R&D. The programs seek to address the most prevalent diseases in the Kingdom that have a global impact, aligning with the national vision of providing exceptional healthcare through innovation. Additionally, the initiative will accelerate the establishment of applied research, ensuring a direct impact on patient care, while creating a world-class medical R&D, biotechnology, and biopharmaceutical hub at MNG-HA/KAIMRC. Ultimately, the goal is to rapidly develop one of the world’s leading precision medicine hubs in Saudi Arabia.
• In November 2024, Henlius entered into a strategic partnership with AL-TIRYAQ AL-KHALAWI Medical Company, a subsidiary of Saudi Arabia's renowned Fakeeh Family business group in the healthcare sector. The collaboration will involve the establishment of joint ventures in Saudi Arabia, combining Henlius’ expertise in the research, development, and manufacturing of biologics with SVAX's local strengths in registration, market access, and commercialization. This partnership aims to accelerate the global registration and commercialization of multiple Henlius products, while improving access to advanced biologics across the Middle East, North Africa, and Türkiye (MENAT) region, ultimately benefiting more patients.

Key Market Players

• Saudi Biotechnology Manufacturing Co
• Amgen Middle East FZ LLC
• SaudiVax
• Lifera Omics
• Novartis Saudi Arabia

Report Scope

In this report, the Saudi Arabia Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Saudi Arabia Biotechnology Market, By Product Type:

o   Instruments

o   Reagents

o   Software and Services

• Saudi Arabia Biotechnology Market, By Technology:

o   Nanobiotechnology

o   Tissue Engineering and Regeneration

o   DNA Sequencing

o   Cell-Based Assays

o   Fermentation

o   PCR Technology

o   Chromatography

o   Others

• Saudi Arabia Biotechnology Market, By Region:

o   Eastern

o   Western

o   Northern & Central

o   Southern

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Saudi Arabia Biotechnology Market.

Available Customizations:

Saudi Arabia Biotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Saudi Arabia Biotechnology Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com